Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective

References

• U.S. Census Bureau Population Estimates by Demographic Characteristics. Table 2: annual estimates of the population by selected age groups and sex for the United States: 1 April 2000 to 1 July 2004. Population Division, U.S. Census Bureau: 9 June 2005
   Google Scholar
• Caley CF, Kando JC. SSRI efficacy-finding the right dose. J Psychiatr Pract 2002;8:33-40
   PubMedGoogle Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd edn. Am J Psychiatry 2010;167(Suppl):1-152
   PubMed Web of Science ®Google Scholar
• Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry 2007;164:1189-97
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15
   PubMed Web of Science ®Google Scholar
• Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Van Ganse E, Gregoire J, et al. Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. Int Clin Psychopharmacol 1998;13:11-17
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(22 Suppl):30-3
   PubMed Web of Science ®Google Scholar
• Arnow BA, Blasey C, Manber R, et al. Dropouts versus completers among chronically depressed outpatients. J Affect Disord 2007;97:197-202
   PubMed Web of Science ®Google Scholar
• Eaddy MT, Druss BG, Sarnes MW, et al. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy–results from a managed care administrative claims database. J Manag Care Pharm 2005;11:145-50
   PubMedGoogle Scholar
• Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-32
   PubMed Web of Science ®Google Scholar
• Eaddy M, Bramley T, Regan T. Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors. Manag Care Interface 2003;16:22-7
   PubMedGoogle Scholar
• Liu X, Tepper PG, Able SL. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder. Int Clin Psychopharmacol 2011;26:173-80
   PubMed Web of Science ®Google Scholar
• Liu XC, Gelwicks S, Faries D, et al. Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder. Int Clin Psychopharmacology 2010;25:315-22
   PubMed Web of Science ®Google Scholar
• Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002;288:1403-9
   PubMed Web of Science ®Google Scholar
• Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry 2007;164:1189-97
   PubMed Web of Science ®Google Scholar
• Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Dunner DL, Meyers AL, et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry 2008;69:1383-92
   PubMed Web of Science ®Google Scholar
• Cymbalta package insert. Indianapolis, IN: Eli Lilly and Company, 2011. Available at: http://pi.lilly.com/us/cymbalta-pi.pdf. Accessed June 27, 2011
   Google Scholar
• Liu X, Gelwicks S, Able S, et al. Initial high-dose prescription of duloxetine in patients with major depressive disorder: demographic and clinical predictors. Presented at: ISPOR 12th Annual European Congress, Paris, France, 26 October 2009
   Google Scholar
• Liu XC, Cui Z, Niu L, et al. Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective. Clin Ther In Press
   Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-90
   PubMed Web of Science ®Google Scholar
• Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006;21:367-78
   PubMed Web of Science ®Google Scholar
• Nelson JC, Lu Pritchett Y, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry 2006;8:212-9
   PubMedGoogle Scholar
• Motheral BR, Cox ER, Mager D, et al. Regional variation in prescription use in the United States. Presented at: ISPOR 4th Annual European Congress, Cannes, France, 12 November 2001
   Google Scholar